Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Gilead Sciences (GILD) Declares $0.63 Quarterly Dividend; 3.8% Yield
July 30, 2019 5:21 PM EDTGilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.63 per share, or $2.52 annualized.
The dividend will be payable on September 27, 2019, to stockholders of record on September 13, 2019, with an ex-dividend date of September 12, 2019.
The annual yield on the dividend is 3.8... More
